NCT01091428 2018-06-04Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast CancerTakedaPhase 2 Completed191 enrolled 39 charts